ATE359775T1 - Synergistische zusammensetzungen enthaltend einen alpha-2-delta liganden kombiniert mit einem pdev inhibitor zur behandlung von schmerz - Google Patents

Synergistische zusammensetzungen enthaltend einen alpha-2-delta liganden kombiniert mit einem pdev inhibitor zur behandlung von schmerz

Info

Publication number
ATE359775T1
ATE359775T1 AT03787957T AT03787957T ATE359775T1 AT E359775 T1 ATE359775 T1 AT E359775T1 AT 03787957 T AT03787957 T AT 03787957T AT 03787957 T AT03787957 T AT 03787957T AT E359775 T1 ATE359775 T1 AT E359775T1
Authority
AT
Austria
Prior art keywords
pain
alpha
treatment
compositions containing
synergistic compositions
Prior art date
Application number
AT03787957T
Other languages
English (en)
Inventor
Mark John Field
Richard Griffith Williams
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE359775T1 publication Critical patent/ATE359775T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03787957T 2002-08-15 2003-08-04 Synergistische zusammensetzungen enthaltend einen alpha-2-delta liganden kombiniert mit einem pdev inhibitor zur behandlung von schmerz ATE359775T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0219024.7A GB0219024D0 (en) 2002-08-15 2002-08-15 Synergistic combinations

Publications (1)

Publication Number Publication Date
ATE359775T1 true ATE359775T1 (de) 2007-05-15

Family

ID=9942388

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03787957T ATE359775T1 (de) 2002-08-15 2003-08-04 Synergistische zusammensetzungen enthaltend einen alpha-2-delta liganden kombiniert mit einem pdev inhibitor zur behandlung von schmerz

Country Status (40)

Country Link
EP (1) EP1536782B1 (de)
JP (1) JP2006502139A (de)
KR (2) KR20070009746A (de)
CN (1) CN1674884A (de)
AP (1) AP2005003227A0 (de)
AR (1) AR040871A1 (de)
AT (1) ATE359775T1 (de)
AU (1) AU2003249476B2 (de)
BR (1) BR0313484A (de)
CA (1) CA2495433A1 (de)
CR (1) CR7687A (de)
DE (1) DE60313330T2 (de)
DK (1) DK1536782T3 (de)
EA (1) EA007504B1 (de)
EC (1) ECSP055593A (de)
ES (1) ES2285230T3 (de)
GB (1) GB0219024D0 (de)
GE (1) GEP20084366B (de)
GT (1) GT200300173A (de)
HN (1) HN2003000247A (de)
HR (1) HRP20050136A2 (de)
IL (1) IL166415A0 (de)
IS (1) IS7643A (de)
MA (1) MA27381A1 (de)
MX (1) MXPA05001835A (de)
NO (1) NO20050782L (de)
NZ (1) NZ537818A (de)
OA (1) OA12899A (de)
PA (1) PA8577301A1 (de)
PE (1) PE20040992A1 (de)
PL (1) PL375553A1 (de)
PT (1) PT1536782E (de)
RS (1) RS20050078A (de)
SI (1) SI1536782T1 (de)
TN (1) TNSN05042A1 (de)
TW (1) TW200404531A (de)
UA (1) UA77329C2 (de)
UY (1) UY27936A1 (de)
WO (1) WO2004016259A1 (de)
ZA (1) ZA200500369B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NI200300043A (es) 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
KR20060087560A (ko) * 2003-09-12 2006-08-02 워너-램버트 캄파니 엘엘씨 알파-2-델타 리간드 및 ｓｓｒｉ 및/또는 ｓｎｒｉ를포함하는 우울증 및 불안 장애 치료용 조합물
KR20070039986A (ko) * 2003-09-25 2007-04-13 워너-램버트 캄파니 엘엘씨 알파2델타-단백질에 대한 친화성을 갖는 아미노산
WO2005030184A2 (en) 2003-09-25 2005-04-07 Warner-Lambert Company Llc Therapeutic beta aminoacids
GB0405200D0 (en) * 2004-03-08 2004-04-21 Pfizer Ltd Combinations comprising alpha-2-delta ligands
AU2005264036A1 (en) * 2004-07-09 2006-01-26 Warner-Lambert Company Llc Preparation of beta-amino acids having affinity for the alpha-2-delta protein
ITMI20041447A1 (it) * 2004-07-20 2004-10-20 Zambon Spa Composizione farmaceutica comprendente gabapentina
US20090227562A1 (en) * 2004-08-10 2009-09-10 Pfizer Inc. Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
JP2008512436A (ja) * 2004-09-07 2008-04-24 ファイザー・インク 片頭痛治療用の５−ＨＴ（１）受容体アゴニストとα２δリガンドの組み合わせ
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
MX2009011858A (es) * 2007-04-30 2010-01-14 Adolor Corp Composiciones de (-)-e-10-oh-nt y metodos para su sintesis y uso.
WO2008132589A1 (en) * 2007-05-01 2008-11-06 Pfizer Limited Combinations comprising pregabalin
US20090148532A1 (en) * 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
TWI531362B (zh) 2008-07-21 2016-05-01 艾爾康股份有限公司 具有治療劑遞送能力之眼科裝置
KR101786818B1 (ko) * 2010-07-30 2017-10-18 도레이 카부시키가이샤 신경장애성 동통의 치료제 또는 예방제
WO2012158795A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
AU2012255759B2 (en) 2011-05-17 2017-08-10 Principia Biopharma, Inc. Kinase inhibitors
JP5974084B2 (ja) 2011-05-17 2016-08-23 プリンシピア バイオファーマ インコーポレイテッド チロシンキナーゼ阻害剤
WO2013084182A1 (en) * 2011-12-08 2013-06-13 Glenmark Pharmaceuticals S.A. Pharmaceutical composition that includes a pde4 enzyme inhibitor and an analgesic agent
CA2882367C (en) 2012-09-10 2021-11-09 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
BR112016018948B1 (pt) 2014-02-21 2023-01-17 Principia Biopharma Inc Uso de composto ou sal farmaceuticamente aceitável, ácido sulfônico ou sal de ácido carboxílico de composto, forma amorfa de sal farmaceuticamente aceitável de composto, composição farmacêutica e respectivo uso
PL3233103T3 (pl) 2014-12-18 2021-04-19 Principia Biopharma Inc. Leczenie pęcherzycy
EP3313839A1 (de) 2015-06-24 2018-05-02 Principia Biopharma Inc. Tyrosin-kinase-inhibitoren
KR102515813B1 (ko) 2016-06-29 2023-03-30 프린시피아 바이오파마, 인코퍼레이티드 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴의 변형 방출 제제
CN114195661B (zh) * 2021-12-21 2023-12-22 苏州楚凯药业有限公司 一种苯磺酸米洛巴林的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT934061E (pt) * 1996-07-24 2003-10-31 Warner Lambert Co Isobutilgaba e seus derivados para o tratamento da dor
ES2227896T3 (es) * 1997-12-16 2005-04-01 Warner-Lambert Company Llc Derivados de 1-aminometil-cicloalcanos sustituidos en 1 (=analogos de gabapentina), su preparacion y su uso en el tratamiento de trastornos neurologicos.
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
IL139073A0 (en) * 1999-10-21 2001-11-25 Pfizer Treatment of neuropathy
AU2001286832A1 (en) * 2000-08-30 2002-03-13 Lilly Icos Llc Method for treatment of migraine using PDE5 inhibitors
EA006396B1 (ru) * 2001-04-19 2005-12-29 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл Эл Си Конденсированные бициклические аминокислоты

Also Published As

Publication number Publication date
CR7687A (es) 2005-07-08
TNSN05042A1 (fr) 2007-05-14
RS20050078A (en) 2007-09-21
PE20040992A1 (es) 2004-12-29
IS7643A (is) 2005-01-12
UY27936A1 (es) 2004-03-31
NO20050782L (no) 2005-04-08
EA007504B1 (ru) 2006-10-27
WO2004016259A1 (en) 2004-02-26
HN2003000247A (es) 2007-12-14
CA2495433A1 (en) 2004-02-26
GT200300173A (es) 2007-03-29
NZ537818A (en) 2007-07-27
EA200500207A1 (ru) 2005-08-25
SI1536782T1 (sl) 2007-08-31
DK1536782T3 (da) 2007-07-30
TW200404531A (en) 2004-04-01
BR0313484A (pt) 2005-06-21
CN1674884A (zh) 2005-09-28
EP1536782B1 (de) 2007-04-18
DE60313330D1 (de) 2007-05-31
DE60313330T2 (de) 2008-01-03
IL166415A0 (en) 2006-01-15
AU2003249476A1 (en) 2004-03-03
PL375553A1 (en) 2005-11-28
HRP20050136A2 (en) 2005-06-30
UA77329C2 (en) 2006-11-15
AU2003249476B2 (en) 2008-06-26
AP2005003227A0 (en) 2005-03-31
GEP20084366B (en) 2008-05-13
EP1536782A1 (de) 2005-06-08
GB0219024D0 (en) 2002-09-25
ES2285230T3 (es) 2007-11-16
OA12899A (en) 2006-10-13
PA8577301A1 (es) 2004-03-10
ECSP055593A (es) 2005-04-18
PT1536782E (pt) 2007-06-27
KR20050042154A (ko) 2005-05-04
MXPA05001835A (es) 2005-09-30
AR040871A1 (es) 2005-04-20
JP2006502139A (ja) 2006-01-19
KR20070009746A (ko) 2007-01-18
ZA200500369B (en) 2006-10-25
MA27381A1 (fr) 2005-06-01

Similar Documents

Publication Publication Date Title
ATE359775T1 (de) Synergistische zusammensetzungen enthaltend einen alpha-2-delta liganden kombiniert mit einem pdev inhibitor zur behandlung von schmerz
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
DE50306850D1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
DE60137329D1 (de) Zusammensetzungen zur behandlung von diabetes die einen dp iv-inhibitoren und einen andere antidiabetikum enthalten
DE602004026891D1 (de) Tlr7-liganden zur behandlung von hepatitis c
WO2005021558A3 (en) Proteasome inhibitors and methods of using the same
DE602005019856D1 (de) Mittel zur behandlung von hyperlipidämie mit pitavastatinen und eicosapentaensäure
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
WO2005016859A3 (en) Proteasome inhibitors and methods of using the same
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
ATE513550T1 (de) Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung
DE602005022427D1 (de) Verwendung von flibanserin bei der behandlung von prämenstruellen störungen
EP1581169A4 (de) Zusammensetzungen und verfahren zurbehandlung von erkrankungen in verbindung mit natürlichen killerzellen
ATE515261T1 (de) Zusammensetzungen zur behandlung von diabetes
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
DE602004020660D1 (de) Pyrazolylderivative in form von arzneimitteln zur behandlung von akuten oder chronischen neuronalen regressionen
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE602005019341D1 (de) System zur Behandlung von Sterilisationskassetten mit visuellem Dual-Kode Leser
ATE335008T1 (de) Eisen-dextrin verbindung zur behandlung von anämien durch eisenmangel
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602004022153D1 (de) Verbindungen zur behandlung von obesitas
DE60325496D1 (de) Verwendung von dihydroimidazolonen zur behandlung von epilepsie bei hunden
DE60121047D1 (de) Pharmazeutische zusammensetzung zur behandlung von phimose mit einem topischen corticosteroid
DE50308460D1 (de) Verwendung von ambroxol zur behandlung von chronischen schmerzen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1536782

Country of ref document: EP

REN Ceased due to non-payment of the annual fee